BridgeBio Pharma, Inc. (BBIO) Cash Flow Statement

Because net income and operating cash flow are both negative in most periods, the ratio is less informative than the absolute gap, which reflects non-cash items such as stock-based compensation of $39.9M in 2026Q3 that inflate the cash-to-earnings relationship. The sharp swing in 2024Q2 when OCF turned positive on a milestone-driven quarter illustrates how lumpy collaboration receipts distort conversion quality. Investors should monitor whether operating cash burn narrows as product revenue becomes a larger share of the total.

The improvement from the Q1 trough suggests working capital swings and revenue timing are driving much of the quarter-to-quarter movement rather than a durable structural shift. Capital expenditure is negligible, so FCF is essentially operating cash flow, meaning the burn is driven by the operating cost base rather than investment spending. Whether the margin turns durably positive will depend on sustained Attruby revenue exceeding operating outlays.

The magnitude of these swings relative to net income implies that reported quarterly cash flow is heavily influenced by the timing of collections and milestone recognition rather than underlying operating efficiency. The large inflow in 2024Q2 appears non-recurring and should not be extrapolated when judging cash generation. Analysts should treat trailing multi-quarter averages as more reliable than any single period's working capital contribution.

Repurchasing shares while operating cash flow is negative implies that buybacks are being funded from the balance sheet cash position rather than from internally generated resources. This may indicate management confidence in the valuation, but it also reduces the liquidity cushion available for clinical and commercial needs. Investors should monitor whether repurchases continue as cash reserves decline.

The consistent direction of both net income and operating cash flow, with cumulative losses far exceeding the single positive OCF quarter, suggests the company has not yet reached a self-funding operating profile. The divergence between accounting losses and cash burn is narrower than in many biotech peers, which points to a cost base that is largely cash-settled rather than heavily non-cash. Continued funding needs remain the central analytical question.